MedPath

Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke
Associated Therapies
-

Effect of Add-on Spironolactone to Losartan Versus Losartan Alone on Peritoneal Membrane Among Peritoneal Dialysis Patients

Phase 4
Conditions
End Stage Renal Disease
Peritoneal Dialysis
Interventions
First Posted Date
2019-05-17
Last Posted Date
2019-09-04
Lead Sponsor
Chiang Mai University
Target Recruit Count
84
Registration Number
NCT03953950
Locations
🇹🇭

Pharmacoepidemiology and Statistics Research Center, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand

Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study

Phase 2
Conditions
Glioblastoma
Brain Metastases
Interventions
First Posted Date
2019-05-15
Last Posted Date
2023-11-01
Lead Sponsor
Kyrre Eeg Emblem
Target Recruit Count
165
Registration Number
NCT03951142
Locations
🇳🇴

Oslo University Hospital, Oslo, Norway

The Pharmacokinetic Interaction Between Amlodipine and Losartan

First Posted Date
2019-04-11
Last Posted Date
2019-04-12
Lead Sponsor
Korea University Anam Hospital
Target Recruit Count
24
Registration Number
NCT03912285
Locations
🇰🇷

Dept. of Clinical Pharmacology & Toxicology, Anam Hospital, Korea University College of Medicine, Seoul, Korea, Republic of

Losartan + Sunitinib in Treatment of Osteosarcoma

Phase 1
Recruiting
Conditions
Osteosarcoma
Interventions
First Posted Date
2019-04-03
Last Posted Date
2024-12-20
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
41
Registration Number
NCT03900793
Locations
🇺🇸

Children's Hospital Colorado, Aurora, Colorado, United States

🇺🇸

University of Colorado Hospital, Aurora, Colorado, United States

🇺🇸

Children's Hospital of Atlanta, Atlanta, Georgia, United States

A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension

Phase 2
Completed
Conditions
Hypertension
Interventions
Drug: HCP1803
Drug: Amlodipine
Drug: Losartan
Drug: Placebo
First Posted Date
2019-04-01
Last Posted Date
2022-07-14
Lead Sponsor
Hanmi Pharmaceutical Company Limited
Target Recruit Count
248
Registration Number
NCT03897868
Locations
🇰🇷

Donggguk University Ilsan Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1
Terminated
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Anatomic Stage IV Breast Cancer AJCC v8
Anemia
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Castration-Resistant Prostate Carcinoma
Interventions
First Posted Date
2019-03-18
Last Posted Date
2024-03-04
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
2
Registration Number
NCT03878524
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

First Posted Date
2019-03-06
Last Posted Date
2023-06-08
Lead Sponsor
Pfizer
Target Recruit Count
56
Registration Number
NCT03864042
Locations
🇨🇦

Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada

🇺🇸

UC Irvine Health, Orange, California, United States

🇺🇸

University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States

and more 26 locations

Losartan and Emotional Memory

Not Applicable
Completed
Conditions
Memory
Learning
Interventions
First Posted Date
2018-12-04
Last Posted Date
2018-12-06
Lead Sponsor
University of Oxford
Target Recruit Count
53
Registration Number
NCT03763409
Locations
🇬🇧

Department of Psychiatry, University of Oxford, Oxford, United Kingdom

Nighttime Losartan in Continous Ambulatory Peritoneal Dialysis (NVCAPD)

Phase 4
Conditions
Hypertension,Nephropathy
Interventions
First Posted Date
2018-10-02
Last Posted Date
2018-11-05
Lead Sponsor
Fifth Affiliated Hospital, Sun Yat-Sen University
Target Recruit Count
68
Registration Number
NCT03692013

Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease

Phase 4
Completed
Conditions
Aortic Stenosis
Aortic Regurgitation
Hypertension
LVM
Left Ventricular Hypertrophy
Interventions
Drug: Amlodipine 5mg
Drug: Losartan
Drug: Losartan and Amlodipine
Drug: Amlodipine/Losartan/Chlorthalidone
Drug: current treatment
First Posted Date
2018-09-11
Last Posted Date
2022-09-15
Lead Sponsor
Hanmi Pharmaceutical Company Limited
Target Recruit Count
128
Registration Number
NCT03666351
Locations
🇰🇷

10 Institutions Including Asan Medical Center, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath